Cortexyme is a late-stage biotechnology company focused on leveraging its proprietary AIDE technology platform to develop innovative therapies for rare diseases, particularly targeting Ataxia-Telangiectasia (A-T) with its lead product eDSP, which encapsulates dexamethasone sodium phosphate in autologous red blood cells to improve treatment efficacy and reduce adverse effects
Cortexyme is a late-stage biotechnology company focused on leveraging its proprietary AIDE technology platform to develop innovative therapies for rare diseases, particularly targeting Ataxia-Telangiectasia (A-T) with its lead product eDSP, which encapsulates dexamethasone sodium phosphate in autologous red blood cells to improve treatment efficacy and reduce adverse effects.